Beyond Biotech - the podcast from Labiotech

The best biotech conversations you missed this summer

Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best mom

Rewriting the rules of genetic medicine with tRNA therapeutics

Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRN

How Evox Therapeutics is targeting CNS diseases with exosomes

Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced

BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech

Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who

Beyond biology: Nanobiotix's physics-first approach to cancer

What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Na

How Cancer Research Horizons is building the future of childhood cancer medicines

Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically

Why Western pharma is sleeping on China's circular RNA revolution

RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone o

Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's

Today we welcome Gene Mack, President and CEO of Gain Therapeutics.  With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership

This nonprofit is building the ecosystem to cure epidermolysis bullosa

Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blist

How BIO-Europe is expanding beyond dealmaking in 2026

The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the indust

Turning cancer cell dependencies into targeted therapies

Today I’m delighted to welcome Andy Parker, CEO of Step Pharma. With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, and venture capital, Andy has

The first PROTAC is here. What comes next in protein degradation?

Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuin

De-risking neurology drug development with better mouse models

Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader.  Our discussion focuses on a persistent challenge in

BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler

This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceu

Advancing corticosteroids and hormonal therapies for supply and scale

Today we’re diving into the world of corticosteroids and hormonal therapies — essential APIs that treat everything from asthma and autoimmune diseases to diabetes and end

Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media

Welcome to episode 200! Today I’m delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The

World MS Day Special: Immunic reveals new hope for progressive MS

Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics.  With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclero

The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of L

Freeze variability, not progress: strengthen your cell therapy supply chain from the start

Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that

Making labs smarter for scientific breakthroughs

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. Ryan's journey spans groundbreaking work in virotherapy and gene